Reports Q3 revenue $17.7B, consensus $14.95B. Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We delivered another strong quarter of results as we continued to execute with discipline, strengthen our commercial position and advance our pipeline. I am pleased with the performance of our product portfolio in the third quarter as we continued to achieve exceptional growth with our Oncology products, including strong revenue growth contributions from Padcev, Xtandi, Lorbrena and Braftovi/Mektovi, and as we delivered on heightened demand for Paxlovid during the recent COVID-19 wave.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Notable companies reporting before tomorrow’s open
- Options Volatility and Implied Earnings Moves This Week, October 28 – November 01, 2024
- PFE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pfizer maintained Neutral on analyst transfer at Citi
- Pfizer: CDC Advisory Committee expands recommendation for use of Prevnar 20